By Market Intelligence Team

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News On November 18, 2003, Britannia Pharmaceuticals Limited (London, United Kingdom) signed an agreement with US WorldMeds LLC (Louisville, Kentucky) to further develop and market Britannia's non-opiate, non-addictive addiction treatment medication, lofexidine hydrochloride (lofexidine), in the United States. Lofexidine is used to manage the physical symptoms of opiate (e.g., methadone, heroin, dihydrocodeine) withdrawal such as chills, sweating, vomiting, stomach cramps, and muscle pain. In the United Kingdom, the medication has been used in approximately 200,000 . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options
OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News On November 18, 2003, Britannia Pharmaceuticals Limited (London, United Kingdom) signed an agreement with US WorldMeds LLC (Louisville, Kentucky) to further develop and market Britannia's non-opiate, non-addictive addiction treatment medication, lofexidine hydrochloride (lofexidine), in the United States. Lofexidine is used to manage the physical symptoms of opiate (e.g., methadone, heroin, dihydrocodeine) withdrawal such as chills, sweating, vomiting, stomach cramps, and muscle pain. In the United Kingdom, the medication has been used in approximately 200,000 . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!